Business NewsPR NewsWire • DS Biopharma (DS) Announces Spin-out Company Focused on Fibrotic Conditions and Pulmonary Disorders

DS Biopharma (DS) Announces Spin-out Company Focused on Fibrotic Conditions and Pulmonary Disorders

DS Biopharma (DS) Announces Spin-out Company Focused on Fibrotic Conditions and Pulmonary Disorders

DUBLIN, August 22, 2016 /PRNewswire/ -- Afimmune will continue development of DS102  DS Biopharma will focus on dermatological conditions  DS Biopharma (DS), a privately held drug discovery and development company with industry-leading expertise in lipid science, today...

View More : http://www.prnewswire.com/news-releases/ds-biopharma-ds-announces-spin-out-company-focused-on-fibrotic-conditions-and-pu...
Releted News by prnewswire
Commercial and Industrial Property Insurer FM Global Breaks Ground on S$80-Million Unique Loss Prevention Training and Operations Center in Singapore
Global Elastomeric Coating Market Growing 15% CAGR to 2021
DS Biopharma (DS) Announces Spin-out Company Focused on Fibrotic Conditions and Pulmonary Disorders
CPFD Software stellt Technical Advisory Board vor
Studio Science Appoints Director of Business Development
CDK Global becomes Technology Partner for Inland Group